{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T08:00:55Z","timestamp":1795075255388,"version":"4.10.2"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T00:00:00Z","timestamp":1623024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","award":["GN16RH008"],"award-info":[{"award-number":["GN16RH008"]}],"id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["RE\/13\/5\/30177"],"award-info":[{"award-number":["RE\/13\/5\/30177"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Studies have suggested phosphodiesterase 4 (PDE4) inhibition may be associated with weight loss and other cardiometabolic benefits. We evaluated the effect of the PDE4 inhibitor apremilast on body weight and composition, glucose homeostasis, lipid profiles and vascular function in psoriatic disease and whether weight change correlated with therapeutic response.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a prospective, open-label study (Immune Metabolic Associations in Psoriatic Arthritis) of adults receiving apremilast 30\u2009mg as part of routine care for PsA and\/or psoriasis. Cardiometabolic, anthropometric and disease activity assessments were performed at baseline (pre-apremilast) and at months 1, 3 and 6 of apremilast treatment in 60 patients. A subgroup underwent further assessment of endothelial function, body composition and adipocyte morphology.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In patients (median age 54.5\u2009years, 63% women, median BMI 33.2\u2009kg\/m2), apremilast was associated with a mean weight loss of 2.2\u2009kg (95% CI 1.4, 3.0; P\u2009&amp;lt;\u20090.001) and a mean BMI decrease of 0.8\u2009kg\/m2 (95% CI 0.5, 1.2; P\u2009&amp;lt;\u20090.001) after 6\u2009months of treatment. Body composition analysis demonstrated a reduction in total abdominal fat [mean decrease 0.52\u2009L (95% CI 0.08, 0.96), P\u2009=\u20090.022], principally subcutaneous adipose tissue [mean decrease 0.37\u2009L (95% CI 0.05, 0.68), P\u2009=\u20090.022]. There was no change in adipocyte diameter, haemoglobin A1c, lipid, glucagon-like peptide-1 or vascular function. Psoriatic disease activity improved with apremilast, although this was not correlated with weight change.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Following apremilast treatment, we observed weight loss, principally abdominal subcutaneous fat, and improvement in psoriatic disease activity. The latter was independent of weight change, suggesting apremilast likely acts through direct immunological mechanisms.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keab474","type":"journal-article","created":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T19:10:51Z","timestamp":1622920251000},"page":"1026-1034","source":"Crossref","is-referenced-by-count":35,"title":["Effect of the phosphodiesterase 4 inhibitor apremilast on cardiometabolic outcomes in psoriatic disease\u2014results of the Immune Metabolic Associations in Psoriatic Arthritis study"],"prefix":"10.1093","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6136-8349","authenticated-orcid":false,"given":"Lyn D","family":"Ferguson","sequence":"first","affiliation":[{"name":"Institute of Cardiovascular and Medical Sciences, University of Glasgow"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Cathcart","sequence":"additional","affiliation":[{"name":"Glasgow Clinical Research Facility, Glasgow Royal Infirmary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Rimmer","sequence":"additional","affiliation":[{"name":"Glasgow Clinical Research Facility, Glasgow Royal Infirmary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Semple","sequence":"additional","affiliation":[{"name":"Glasgow Clinical Research Facility, Glasgow Royal Infirmary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katriona","family":"Brooksbank","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular and Medical Sciences, University of Glasgow"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caron","family":"Paterson","sequence":"additional","affiliation":[{"name":"Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary","family":"Brown","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular and Medical Sciences, University of Glasgow"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Harvie","sequence":"additional","affiliation":[{"name":"Raigmore Hospital, Inverness, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Gao","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular and Medical Sciences, University of Glasgow"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Radjenovic","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular and Medical Sciences, University of Glasgow"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Welsh","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular and Medical Sciences, University of Glasgow"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain B","family":"McInnes","sequence":"additional","affiliation":[{"name":"Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveed","family":"Sattar","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular and Medical Sciences, University of Glasgow"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1802-7311","authenticated-orcid":false,"given":"Stefan","family":"Siebert","sequence":"additional","affiliation":[{"name":"Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,6,7]]},"reference":[{"key":"2022030208050535000_keab474-B1","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41584-019-0256-0","article-title":"Cardiometabolic comorbidities in RA and PsA: lessons learned and future directions","volume":"15","author":"Ferguson","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"2022030208050535000_keab474-B2","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1136\/annrheumdis-2012-202812","article-title":"Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor \u03b1 blockers","volume":"73","author":"Di Minno","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2022030208050535000_keab474-B3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13075-019-1810-5","article-title":"Weight loss improves disease activity in patients with psoriatic arthritis and obesity: an interventional study","volume":"21","author":"Klingberg","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2022030208050535000_keab474-B4","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/j.bcp.2012.01.001","article-title":"Apremilast mechanism of action and application to psoriasis and psoriatic arthritis","volume":"83","author":"Schafer","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"2022030208050535000_keab474-B5","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/annrheumdis-2015-207963","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)","volume":"75","author":"Edwards","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2022030208050535000_keab474-B6","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/bjd.14164","article-title":"Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)","volume":"173","author":"Paul","year":"2015","journal-title":"Br J Dermatol"},{"key":"2022030208050535000_keab474-B7","doi-asserted-by":"crossref","first-page":"AB89","DOI":"10.1016\/j.jaad.2019.06.346","article-title":"Long-term hemoglobin A1c changes with apremilast in patients with psoriasis and psoriatic arthritis: pooled analysis of phase 3 ESTEEM and PALACE trials and phase 3b LIBERATE trial","volume":"81","author":"Puig","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2022030208050535000_keab474-B8","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1476-5381.2009.00194.x","article-title":"The role of the PDE4D cAMP phosphodiesterase in the regulation of glucagon-like peptide-1 release","volume":"157","author":"Ong","year":"2009","journal-title":"Br J Pharmacol"},{"key":"2022030208050535000_keab474-B9","article-title":"PDE4 inhibition could improve endothelial and adipose tissue dysfunction associated with psoriatic arthritis, key processes in cardiovascular disease","volume":"71(Suppl 10","author":"Arias de la Rosa","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2022030208050535000_keab474-B10","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2022030208050535000_keab474-B11","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.2337\/diacare.21.12.2191","article-title":"Correct homeostasis model assessment (HOMA) evaluation uses the computer program","volume":"21","author":"Levy","year":"1998","journal-title":"Diabetes Care"},{"key":"2022030208050535000_keab474-B12","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"key":"2022030208050535000_keab474-B13","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/ard.2008.102053","article-title":"Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment","volume":"69","author":"Coates","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2022030208050535000_keab474-B14","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1093\/rheumatology\/keaa604","article-title":"Psoriatic arthritis is associated with adverse body composition predictive of greater coronary heart disease and type 2 diabetes propensity \u2013 a cross-sectional study","volume":"60","author":"Ferguson","year":"2021","journal-title":"Rheumatology"},{"key":"2022030208050535000_keab474-B15","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1016\/j.jacc.2004.08.062","article-title":"Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia","volume":"44","author":"Bonetti","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"2022030208050535000_keab474-B16"},{"key":"2022030208050535000_keab474-B17","doi-asserted-by":"crossref","first-page":"AB227","DOI":"10.1016\/j.jaad.2015.02.920","article-title":"Change in weight with apremilast, an oral phosphodiesterase 4 inhibitor: Pooled analysis of the ESTEEM 1 and ESTEEM 2 trials","volume":"72","author":"Reich","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"2022030208050535000_keab474-B18","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1007\/s001250051560","article-title":"Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts type II diabetes independent of insulin resistance","volume":"43","author":"Weyer","year":"2000","journal-title":"Diabetologia"},{"key":"2022030208050535000_keab474-B19","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.2337\/dc13-2395","article-title":"Changes in subcutaneous fat cell volume and insulin sensitivity after weight loss","volume":"37","author":"Andersson","year":"2014","journal-title":"Diabetes Care"},{"key":"2022030208050535000_keab474-B20","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/1346-8138.15293","article-title":"Real life experience of apremilast in psoriasis and arthritis psoriatic patients: preliminary results on metabolic biomarkers","volume":"47","author":"Mazzilli","year":"2020","journal-title":"J Dermatol"},{"key":"2022030208050535000_keab474-B21","doi-asserted-by":"crossref","first-page":"E1720","DOI":"10.1210\/jc.2011-2886","article-title":"Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus","volume":"97","author":"Wouters","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2022030208050535000_keab474-B22","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1007\/s00125-012-2632-z","article-title":"The glucose-lowering effects of the PDE4 inhibitors roflumilast and roflumilast-N-oxide in db\/db mice","volume":"55","author":"Vollert","year":"2012","journal-title":"Diabetologia"},{"key":"2022030208050535000_keab474-B23","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/art.22530","article-title":"Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors","volume":"57","author":"Gonzalez-Juanatey","year":"2007","journal-title":"Arthritis Rheum"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keab474\/39309931\/keab474.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/3\/1026\/42672274\/keab474.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/3\/1026\/42672274\/keab474.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T08:09:23Z","timestamp":1646208563000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/61\/3\/1026\/6294317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,7]]},"references-count":23,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,6,7]]},"published-print":{"date-parts":[[2022,3,2]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab474","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,3,1]]},"published":{"date-parts":[[2021,6,7]]}}}